Your capability, your scale, your territories, the part of the pipeline you serve, even what you've decided not to chase: all of it changes what a good opportunity looks like. We build your definition first, then measure everything against it.
Most intelligence tools are built once and sold to everyone. You get filters for phase, therapeutic area, geography and sponsor type, and you rebuild your market from someone else's categories every time.
The real determinants are nuance: the modalities you handle well, the study size where you compete, the regions where you're different, and the work you've chosen to leave alone. None of that fits in a dropdown.
What is a program you would drop everything for, and why that one? Where do you win against larger competitors, and where do you lose? What looks promising on paper and never converts?
Your answers become a written market definition, tested against deals you won, deals you lost, and opportunities that never materialized. If it can't separate those three, it isn't finished. You keep it whether or not you continue with us.
That's why a second market is configuration rather than a rebuild. The instrument stays the same; the rule changes.
Pick a company you know as well as anyone: an account you've worked for years, or a program you've been tracking.
You see where each of its programs sits and what changed recently. Every line points at the record it came from, so you can check the answer against what you know while we're still talking.
A commercial lead and a rep need different things from the same reading.
Accounts ranked, what moved this window, and where the live studies are by phase, drug type and indication.
One per account: what to do this month, the account at a glance, whether they can pay, where their sites are, and what you still need to find out.
Bring an account you know well and an opportunity you lost. Those two things tell us more about your market than any briefing document could.
Start a conversation Who is behind this